MedGuide-Only REMS Will Be The Exception, Not The Norm, As FDA Relaxes Policy

FDA’s proposed new benchmark for incorporating a Medication Guide in a Risk Evaluation and Mitigation Strategy would reduce the regulatory burden on sponsors whose products do not warrant restricted distribution measures.